EPM editor Reece Armstrong sits down with Panna Sharma, CEO of Lantern Pharma to discuss what an Initial Public Offering (IPO) of $27 million means for the company and where this biotech is headed next.
When I first spoke to Panna Sharma in the middle of 2019, I was intrigued by his tenacity to place the company he’d recently joined as CEO, Lantern Pharma, at the forefront of the oncology market.
During that conversation, Sharma spoke about the need for a change in how healthcare approached treating cancer patients, how precision medicine was key to this approach, and how Lantern’s artificial intelligence (AI) platform RADR, could help identify the drugs that work best against specific types of cancers.